How florbetapir could accelerate Alzheimer's research

03/7/2013 |

The practice of beta-amyloid imaging to help diagnose Alzheimer's disease, while slowly evolving, still faces challenges and uncertainties, experts say. Health care providers are hesitant to adopt the use of scans with florbetapir because the procedure is not reimbursed by Medicare and private insurers, in part because of concerns about how the tests will affect patient management. However, the reimbursement question is likely to be resolved by the end of the year, and experts are hopeful increased utilization of the imaging tests will funnel more patients into clinical trials, accelerating research into therapies.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN